ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan
08 nov. 2023 16h05 HE
|
ReShape Lifesciences Inc
Third Quarter Core Operating Expenses Reduced 37% Compared to Third Quarter of 2022 Cost Reduction Plan To Reduce Operating Expenses In 2024 by Over 40% Compared to 2023 Conference Call to be Held...
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update
06 nov. 2023 08h31 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will...
ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering
29 sept. 2023 12h30 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., Sept. 29, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of...
ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI
22 sept. 2023 08h31 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., Sept. 22, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul...
ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System
21 sept. 2023 08h31 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing...
ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System
19 sept. 2023 08h31 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the...
ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device
14 sept. 2023 08h31 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the...
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update
07 août 2023 16h05 HE
|
ReShape Lifesciences Inc
Company Executing Its Plan for Growth; Achieves Continued Improvement in Operational Effectiveness Reducing Second Quarter Operating Expenses by 53% Compared to Second Quarter of 2022 ...
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Provide Corporate Update
03 août 2023 16h05 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will...
ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software
29 juin 2023 08h31 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing...